Beef Cattle Vaccinated Against E. coli O157:H7



    - Top Meadow Farms world's first commercial adopter of vaccine -

    BELLEVILLE, ON, Sept. 24 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC),
a research-based, technology-driven Canadian biopharmaceutical company, today
announced that its vaccine against E. coli O157:H7 in cattle has been used for
the first time by a commercial beef producer. Top Meadow Farms, an
Ontario-based producer of premium beef, integrated use of the E. coli O157:H7
vaccine into its Top in Field(TM) cattle rearing standards, under the auspices
of Canadian Food Inspection Agency (CFIA) regulations governing the sale of
the vaccine in Canada.
    "Top Meadow is committed to producing beef that is of the best possible
taste and healthfulness," stated Kym Anthony, owner of Top Meadow Farms. "The
Bioniche vaccine provides an important pre-harvest intervention against E.
coli O157:H7 that we are very pleased to add to our CFIA-audited Top in
Field(TM) feed and husbandry protocols. Equally, we are pleased to have the
support of retailers of our beef, such as the Highland Farms grocery chain and
the award winning Via Allegro restaurant: All of us take food safety to be a
core obligation."
    "The adoption of our vaccine by Top Meadow Farms provides evidence that a
beef producer recognizes the environmental and public health benefits that can
result from reducing the shed of E. coli O157:H7 bacteria by cattle," said
Graeme McRae, President & CEO of Bioniche Life Sciences Inc. "Shed bacteria
can contaminate food, water and the environment, and human exposures to this
pathogen result in an estimated 100,000 cases of illness per year in North
America."
    The vaccine remains under review by The Canadian Food Inspection Agency
(CFIA) and The United States Department of Agriculture (USDA). In the course
of its review process, the CFIA notified Bioniche last December that it was
agreeable to issuing permits under the Permit to Release Veterinary Biologics
regulations. These regulations allow cattle owners, through their
veterinarians, to request vaccine be supplied to them by Bioniche.
    Since that time, Bioniche has commenced production of the E. coli O157:H7
cattle vaccine at its Belleville, Ontario facility. This supply is now being
provided to veterinarians requesting vaccine under the Canadian Permit to
Release regulations. Bioniche will continue to scale up as full domestic and
international approvals are received. Until such approvals are received, all
vaccine will be shipped to Canadian veterinarians as permit requests are
received and approved by the CFIA.
    In order to progress from shipping under permits to a full license, the
CFIA indicated that Bioniche was required to provide additional data
confirming reduction in E. coli O157:H7 shedding by vaccinated animals. This
information was provided to the CFIA in the spring and is currently under
review.

    About Bioniche Life Sciences Inc.

    Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
195 skilled personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop proprietary
cancer therapies supported by revenues from marketed products in human and
animal health. For more information, please visit www.Bioniche.com. For more
information about E. coli O157:H7, please visit www.fightecoli.com.

    Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

    %SEDAR: 00013159EF




For further information:

For further information: Jennifer Shea, Corporate Communications &
Investor Relations Manager, Bioniche Life Sciences Inc., Telephone: (613)
966-8058, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com

Organization Profile

Telesta Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890